Etiological Surveillance of Male Urethritis Syndrome in South Africa: 2019 to 2020
- PMID: 35551168
- DOI: 10.1097/OLQ.0000000000001647
Etiological Surveillance of Male Urethritis Syndrome in South Africa: 2019 to 2020
Abstract
Background: In South Africa, male urethritis syndrome (MUS) is the most common sexually transmitted infection (STI) syndrome in men. We determined the distribution of STI etiologies and the susceptibility profiles of Neisseria gonorrhoeae isolates from men presenting with MUS to 3 sentinel surveillance health care facilities. Secondary objectives were to determine the seroprevalence of coinfections (HIV, syphilis, herpes simplex virus 2).
Methods: Consecutive, consenting men with symptomatic urethral discharge were enrolled between January 1, 2019, and December 31, 2020. Genital discharge swab and blood specimens were collected and transported to a central STI reference laboratory in Johannesburg, South Africa.
Results: Among 769 men enrolled, N. gonorrhoeae was the commonest cause of MUS (674 [87.8%]; 95% confidence interval [CI], 85.2%-89.9%), followed by Chlamydia trachomatis (161 [21.0%]; 95% CI, 18.2%-24.0%). Of 542 cultivable N. gonorrhoeae isolates, all were susceptible to ceftriaxone (modal minimum inhibitory concentration, 0.004 mg/L) and azithromycin (modal minimum inhibitory concentration, 0.128 mg/L). Seroprevalence rates of HIV, syphilis, and HSV-2 were 21.4% (95% CI, 18.5%-24.5%), 2.3%, and 50.1%, respectively. Condom use at last sexual encounter was reported by only 7%, less than 50% had been medically circumcised, and only 66.7% (58 of 87) who self-reported an HIV-positive status were adherent on antiretroviral drugs.
Conclusions: Neisseria gonorrhoeae and C. trachomatis were the predominant causes of MUS. Currently recommended dual ceftriaxone and azithromycin therapy are appropriate for MUS syndromic management; however, surveillance must be maintained to timeously detect emerging and increasing gonococcal resistance. Clinic-based interventions must be intensified in men seeing sexual health care to reduce the community transmission and burden of STI and HIV.
Copyright © 2022 American Sexually Transmitted Diseases Association. All rights reserved.
Conflict of interest statement
Conflict of Interest and Source of Funding: All authors have no conflicts of interest to declare. Funding for this work was obtained from the operational cost center of the Centre for HIV & STI at the National Institute for Communicable Diseases, Johannesburg, South Africa.
References
-
- Primary Healthcare Standard Treatment Guideline and Essential Medicine List. 6th ed. Pretoria, Republic of South Africa: National Department of Health, 2018.
-
- Epidemiological Comments. Pretoria, South Africa: National Department of Health; 2008; 3.
-
- Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae . Geneva, Switzerland: World Health Organization, 2012.
-
- Kularatne R, Radebe F, Kufa-Chakezha T, et al. Sentinel Surveillance of Sexually Transmitted Syndrome Aetiologies and HPV Genotypes Among Patients Attending Primary Healthcare Facilities in South Africa, April 2014–September 2015. Johannesburg, South Africa: National Institute for Communicable Diseases, 2017.
-
- Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: Past, evolution, and future. Clin Microbiol Rev 2014; 27:587–613.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
